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Abstract
Background: Intestinal ischemia/reperfusion (IR) injury is a serious and triggering event in the development of
remote organ dysfunction, from which the lung is the main target. This condition is characterized by intense
neutrophil recruitment, increased microvascular permeability. Intestinal IR is also responsible for induction of adult
respiratory distress syndrome, the most serious and life-threatening form of acute lung injury. The purpose of this
study was to investigate the effect of annexin-A1 protein as an endogenous regulator of the organ remote injury
induced by intestinal ischemia/reperfusion. Male C57bl/6 mice were subjected to intestinal ischemia, induced by
45 min occlusion of the superior mesenteric artery, followed by reperfusion.
Results: The intestinal ischemia/reperfusion evoked a high intensity lung inflammation as indicated by the number
of neutrophils as compared to control group. Treatment with annexin-A1 peptidomimetic Ac2-26, reduced the
number of neutrophils in the lung tissue and increased its number in the blood vessels, which suggests a
regulatory effect of the peptide Ac2-26 in the neutrophil migration. Moreover, the peptide Ac2-26 treatment was
associated with higher levels of plasma IL-10.
Conclusion: Our data suggest that the annexin-A1 peptidomimetic Ac2-26 treatment has a regulatory and
protective effect in the intestinal ischemia/reperfusion by attenuation of the leukocyte migration to the lung and
induction of the anti-inflammatory cytokine IL-10 release into the plasma. The anti-inflammatory action of annexin-
A1 and its peptidomimetic described here may serve as a basis for future therapeutic approach in mitigating
inflammatory processes due to intestinal ischemia/reperfusion.
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Background
Intestinal ischemia/reperfusion (I/R) injury is a serious and
triggering event in the development of remote organ
dysfunction, of which the lung is the main target. Indeed,
intestinal I/R is a well recognized event involved in acute
lung injury (ALI) induction [1]. This condition is character-
ized by intense neutrophil recruitment, increased micro-
vascular permeability and is responsible for induction of
adult respiratory distress syndrome (ARDS), the most
serious and life-threatening form of acute lung injury [2].
Local injury associated with intestinal I/R are responsible
for the release into the blood stream of IL-1β,
TNF-α, prostanoids, oxygen and nitrogen-derived free
radicals. All of these mediators play pivotal role in the
systemic inflammation [3]. Experimental and clinical
evidences suggest that systemic inflammation contributes
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to the induction of pulmonary microvascular permeability,
neutrophil influx and lung function deterioration [4,5].
Moreover, neutrophil migration from blood into lung
compartment is a significant event for acute lung injury
induction [6]. However, endogenous mechanisms under-
lying neutrophil trafficking after intestinal I/R are still
unclear. Thus, it is important to employ new approaches in
order to understand activation and sequestration of neutro-
phils in the intestinal ischemic events [7].
The anti-inflammatory protein annexin-A1 (ANXA1) is a
potent mediator of inflammation resolution and a 37-kDa
member of the annexin family of calcium and
phospholipid-binding proteins, expressed constitutively in
many cells, including neutrophil gelatinase granules [8].
Exogenous AnxA1 or its N-terminal peptidomimetic
(Ac2-26) administration has been shown to elicit protective
anti-inflammatory actions via both in vitro and in vivo
anti-neutrophil migration mechanisms [8-12]. Moreover,
AnxA1 has been shown to have cardio protective effects
against myocardial ischemia and reperfusion injury in rats
and mice, at least in part due to its inhibitory actions on
neutrophils [10,13]. However, the intracellular mechanisms
involved in these actions have not been fully elucidated
[14]. Because of the difficulties in producing a biologically
active recombinant ANXA1 protein, its N-terminal peptide
has been commonly used for in vivo and in vitro studies.
The peptide Ac2-26 shares many of the anti-inflammatory
activities of ANXA1 and as the name suggests, comprises
the acetylated N-terminal sequence of ANXA1 [12,13].
Thus, we hypothesize that organ remote injury induced by
intestinal I/R (notably acute lung injury) could be
influenced by endogenous control by AnxA1.
Material and methods
Animals
Male C57bl/6 mice (20–25 g of body weight), main-
tained on a standard chow pellet diet with tap water
ad libitum were used for all experiments. Animals were
housed at a density of five animals per cage in a room with
controlled lighting (lights on from 8:00 a.m. to 8:00 p.m.)
and temperature (21–23°C). Experiments were performed
according to Committee of Ethics in Animal Research,
FAMERP, SP, Brazil (CEEA; Protocol 585107) and in
conformity with the directives of the European Union.
Intestinal ischemia/reperfusion model
Laparotomy was carried out in mice (n = 10) under
anesthesia with ketamineW [dopalen, Vetbrands, Brazil,
18.6 mg/Kg, intramuscular (i.m.)] and xylasineW (anasedan,
Vetbrands, Brazil, 2.3 mg/Kg, i.m.). The superior mesen-
teric artery was exposed through a midline abdominal inci-
sion and occluded using a microsurgical clip [15]. After
45 min of arterial occlusion, the clip was removed and
intestinal perfusion was re-established. The animals were
sacrificed 2 h and 24 h later by exsanguination, via the
abdominal aorta, under deep anesthesia. The sham oper-
ated group (n = 10) consisted of mice submitted to the
same surgical procedures including mesenteric artery
dissection but not submitted to the arterial occlusion. An
additional group of non-manipulated mice (n = 10) was
added to obtain normal values of the variables studied.
Peptide Ac2-26 treatment
Groups of mice (n = 10) were pretreated with the pep-
tide Ac2-26 (Ac-AMVSEFLKQAWFIENEEQEYVQTVK;
Invitrogen, USA) 1 mg/kg ip.1 h before the intestinal IR.
As a negative control, mice were treated with Ac2-26
(i.p.), or vehicle (PBS) alone.
Blood and bronchoalveolar cell counts
At 2 h and 24 h post-reperfusion, mice were sacrificed as
indicated above and blood samples (100 μL) obtained from
the abdominal artery were diluted 1:10 in Turk’s solution
(0.1% crystal violet in 3% acetic acid) for cell count using a
plastic syringe (1 mL). In a parallel set of experiments,
brochoalveolar lavage (BAL) was performed according to
Riffo-Vasquez et al. [16]. In brief, after semi-excision of the
trachea, a plastic cannula was inserted and the lung was
washed with 1 mL of saline solution (0.9%) containing
6 mM sodium citrate. This operation was repeated twice.
BAL was centrifuged (600 g for 10 min, 4°C), and the cell-
free supernatants were frozen at −80°C for subsequent
cytokine analysis. An aliquot of cell-free supernatant was
used to analyze the protein concentrations in BAL fluid
using Bradford assay kit (Sigma, St. Louis, USA). Cell
pellets were re-suspended with PBS, and an aliquot
(190 μL) was diluted 20:1 in Turk’s solution (3% crystal vio-
let in 20% acetic acid) for cell counts. Total and differential
counting was obtained using a Neubauer chamber utilizing
a x40 objective upon light microscope Axioskop II mot plus
(Zeiss, GR). BAL cells were distinguished as polymorpho-
nuclear (PMN), monocyte/macrophage and lymphocytes,
whereas peripheral blood cells were classified as PMN,
peripheral blood mononuclear cells (PBMN) and lympho-
cytes. All analyses were done by two blinded investigators.
Pulmonary microvascular leakage
Pulmonary vascular permeability was assessed by Evans
blue dye extravasation. In brief, Evans blue dye (25 mg/Kg)
was given intravenously to mice (n = 5 per group) 5 min
before the animals were killed. Then, the lungs perfused
(via the pulmonary artery with pH 7.0 PBS containing
5 IU/mL heparin) and two samples of lung parenchyma
removed. Both were weighted and then one was placed in
formamide (4 mg/mL wet weight) at 20°C for 24 h and the
other was put to dry in oven (60°C) till >constant weight.
The concentration of Evans blue dye extracted in formam-
ide was determined by spectrophotometry at a wavelength
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of 620 nm (Bio-Tek Instruments, USA) using standard
dilution of Evans blue in formamide (0.3–100 mg/mL). The
dry/wet ratio of each lung sample was determined (index of
edema) and used in the final calculation of Evans blue ex-
travasation which was expressed as mg Evans blue/100 g of
dry weight. The expression of the results as a function of
dry weight of tissue avoided under-evaluation of changes
due to edema.
Lung myeloperoxidase (MPO) activity
MPO was measured as an index of the presence of neu-
trophils. Lung tissue samples were obtained from mice
killed after 2 or 24 h of intestinal reperfusion (n = 5 per
group). The lungs were perfused via the pulmonary
artery with pH 7.0 phosphate buffered saline (PBS)
containing 5 IU/mL heparin. Briefly, to normalize the
pulmonary MPO activity among the group, whole lung
was homogenized with 3 mL/g PBS containing 0.5% of
hexadecyltrimethylammonium bromide and 5 mM
EDTA, pH 6.0. The homogenized samples were soni-
cated (Vibra Cell, Sonics Materials, USA) for 1 minute
and were then centrifuged at 37,000 g for 15 min. Sam-
ples of lung homogenates (20 mL) were incubated for
15 min with H2O2 and ortodianisidine; the reaction
was stopped by the addition of 1% NaNO3. Absorbance
was determined at 460 nm using a microplate reader
(Bio-Tek Instruments, USA).
Histopathological analysis
In a new set of experiments, after euthanasia pulmonary ar-
tery was perfused (20 mL of PBS) in a retrograde direction
in order to remove the intravascular blood from the lung.
The lungs were inflated with air, to avoid alveolar collapse,
and fixed in 4% paraformaldehyde, 0.5% glutaraldehyde and
0.1 M sodium phosphate buffer (pH 7.4) for 2 h at 4°C.
The lungs were then fragmented, washed, dehydrated in
ethanol and embedded in LR Gold resin (London Resin,
UK). Sections were cut (1 μm thick) (Leica RM2265, Leica,
GR), mounted on slides, and stained with toluidine
blue. Quantification of leukocytes in tissue samples was
performed with a high-power objective (x40) on Zeiss-
Axioskop 2 light microscope (Carl Zeiss, Jena, Germany),
and measures of the area of analysis was done with the soft-
ware Axiovision (Zeiss, GR). Data was reported as cells/
mm2 (analyzing at least 10 distinct sections per mouse). All
analyses were done by two blinded investigators.
Interleukin 10 and tumoral necrosis factor (TNF)-α
quantification
Aliquots of blood fluids were centrifuged at 4,000 g for
10 min. Anti-inflammatory cytokine IL-10 and TNF-α
concentrations were measured using specific enzyme-
linked immunosorbent assay kits purchased from R&D
System (Abingdon, UK).
Annexin-A1 expression by immunohistochemistry and
western blotting
Lung immunohistochemistry to detect AnxA1 protein was
performed [17]. Sections were blocked with 10%
bovine serum albumin in PBS (PBSA) followed by over-
night incubation at 4°C with the polyclonal rabbit anti-
AnxA1 antibody (1:200 in 1% PBSA; Invitrogen, USA). As a
negative control of the reaction, some sections of lungs
were incubated with non-immune rabbit serum (1:200
working dilution; Sigma-Aldrich) instead of the primary
antibody. A goat anti-rabbit IgG (Fc fragment-specific) anti-
body conjugated to 5 nm colloidal gold (1:100; British
BioCell International, UK) was then used as secondary anti-
body and incubated for 1 h at room temperature. Silver
enhancing solution (British BioCell International) was used
to augment gold particle staining and sections were
counterstained with haematoxylin. Densitometry was
conducted using the Axioskop II microscope (Zeiss,
Germany) and Axiovision (Zeiss) software was used
to determine protein intensity of the sample (arbitrary
0–255 U scale).
To analyze AnxA1 immunoreactivity in the tissue, lung
fragments were homogenized in EDTA free protease inhibi-
tor (Roche, UK). Protein concentration was determined by
the Bradford assay [18]. Equal protein amounts (30 μg)
were diluted with sample buffer and electrophoresed in a
10% polyacrylamide gel in running buffer (0.3% Tris base,
1.44% glycine, 0.1% SDS in distilled water). Proteins were
transferred onto Hybond-C extra nitrocellulose membranes
with a transfer buffer (0.3% Tris base, 1.44% glycine, 20%
methanol in distilled water). Membrane was initially
blocked with 5% non-fat milk solution in TBS containing
0.1% Tween 20, followed by incubation with an antibody
anti-AnxA1 to detect both cleaved (33 kDa) and intact pro-
tein (37 kDa) (1:1000; Invitrogen, USA). The samples were
incubated with HRP-linked anti-mouse secondary antibody
(1:2000; Amersham Biosciences, USA) and the signal was
amplified with ECL kit (Western blotting detection reagent;
Amersham Biosciences, USA) and visualized with a photo-
graphic film (Hyperbond, Amersham Biosciences). This ex-
periment was performed five times with the animals of the
experimental groups.
Statistical analysis
In all cases, data are reported as mean ± SEM of five mice
per group. Statistical differences between groups were de-
termined by one way ANOVA followed by the Bonferroni
test. Values of P <0.05 were considered significant.
Results
Effect of Ac-2-26 treatment on the leukocyte kinetics in
blood and bronchoalveolar lavage after intestinal I/R
The number of peripheral blood neutrophils was signifi-
cantly increased 2 h after reperfusion. However, 24 h
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later, the number of these cells was similar to those in
the control group (naive group: 6.1 ± 0.4; sham group:
6.0 ± 0.2; negative control group saline: 6.1 ± 0.2;
negative control group Ac2-26: 5.9 ± 0.4 × 105/mL). On
the other hand, PBMN and lymphocytes numbers were
reduced (2 and 24 h) after reperfusion compared to
control group (Figure 1 panels A-C).
Pretreatment with peptide Ac2-26 had no effect on the
increases in the values of peripheral blood leukocytes 2 h
after reperfusion. In contrast, 24 h after reperfusion,
Ac2-26 treatment prevented the reduction of circulating
PBMN and PMN numbers as found in non-treated groups
of mice upon intestinal I/R (Figure 1A and 1B). On the
other hand, circulating lymphocytes number was not af-
fected by pretreatment with peptide Ac2-26 (Figure 1C).
In order to verify the effects of intestinal I/R on the cell
recruitment into bronchoalveolar compartment, we quanti-
fied the cells in BAL, 2 h and 24 h after reperfusion. As
Figure 1 Time course of leukocyte influx into the blood. Mice (n = 10 per group) were submitted to intestinal ischemia for 45 min, followed
by reperfusion at 2 and 24 h. At different time points, blood aliquots were collected for polymorphonuclear (PMN) (A), peripheral blood
monocyte (PBMN) (B) and lymphocyte (C) quantification. BAL was also performed to measure PMN (D), monocyte/macrophage (MC) (E) and
lymphocytes number (F). Data are mean ± SEM from two separate experiments with five mice each. *P < 0.05, **P < 0.01 and ***P < 0.001 versus
control group values; ###P < 0.01 versus corresponding intestinal I/R group values.
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shown in Figure 1 PMN were not detected (Figure 1D),
whereas monocyte/macrophages and lymphocytes number
were not altered (Figure 1E and 1F).
Edema and leukocytes infiltration in the lung after
intestinal I/R induction and Ac2-26 treatment in mice
As depicted in Figure 2 (A-C), neutrophil trafficking
from the blood into the lung tissue was affected by
intestinal I/R and Ac-2-26 treatment. Figure 2 (panels D
and E) shows that neutrophils were present in the lung
vessels and connective tissue of the control group
(naive group: 18.1 ± 0.5/135.0 ± 10.0; sham group:
18.5 ± 0.6/138.0 ± 15.0; negative control group saline:
19.5 ± 0.7/139.0 ± 12.0; negative control group Ac2-26:
17.6 ± 0.6/130.0 ± 8.0 neutrophils/mm2). After 2 h of
reperfusion, the neutrophils number in the vascular
vessels was not affected, but a higher number of
transmigrated cells were observed. However, 24 h post
reperfusion, the number of intravascular neutrophils was
increased tremendously.
Pre-treatment with Ac2-26 prevented neutrophil
migration into the lung tissue, as indicated by the
Figure 2 Histopathological analysis of leukocyte influx into the lung tissue. (A) Histological analysis of the control mice lungs indicated the
absence of leukocytes in the vessels (v) and in the lung tissue. (B) After intestinal ischemia-reperfusion, several transmigrated leukocytes were
observed in the lung parenchyma connective tissue (arrows). (C) AnxA1 peptide Ac2-26 treatment prevented leukocytes influx into the lung
tissue (arrowheads). Toluidine blue stain. Bar, 10 μm. (D-E) Cell counting in the histological sections. (D) Semi-quantitative analysis showing
increase in the intravascular neutrophils after intestinal I/R and after peptide Ac2-26 treatment followed by intestinal I/R. (E) Semi-quantitative
analysis showing increase in the transmigrated neutrophils into lung connective tissue after intestinal I/R and reduction after peptide Ac2-26
treatment followed by intestinal I/R. Tissue area was determined by Axiovision Software. (F) MPO activity analysis demonstrated increased number
of neutrophils into lung tissue after intestinal I/R and reduction after peptide Ac2-26 treatment followed by intestinal I/R. (G-I) Mice subjected to
intestinal ischemia/reperfusion (I/R) had significantly increased pulmonary injury, measured by edema and microvascular leak (hole lung and
alveoli). The changes were significantly attenuated by pretreatment with Ac2-26. All data are mean ± SEM from 5 mice per time point. *P < 0.05,
**P < 0.01 and ***P < 0.001 versus control group values; #P < 0.05 and ##P < 0.01 versus corresponding intestinal I/R group values.
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increased number of these cells in the intravascular
compartment 2 h after reperfusion. Besides, transmigra-
tion of neutrophils, 2 and 24 h after reperfusion was also
reduced by prior treatment of mice with Ac-2-26 in
comparison to the non-treated group (Figure 2D and E).
Similar to the histological findings, the intestinal I/R
induces a large increase in MPO content in lung homoge-
nates (5.5 ± 0.5 and 6.6 ± 0.6 optical density for MPO,
respectively 2 and 24 after intestinal I/R) in comparison
with animals from control group (naive group: 1.8 ± 0.5;
sham group: 1.5 ± 0.4; negative control group + saline:
1.6 ± 0.6; negative control group +Ac2-26: 1.2 ± 0.4)
(Figure 2F). This increase was significantly attenuated by
the pretreatment of peptide Ac2-26 (3.2 ± 0.5 and 2.8 ± 0.6,
respectively 2 and 24 after intestinal I/R) (Figure 2F).
To analyze the pulmonary injury in response to intes-
tinal I/R, we evaluate the Evans blue extravasation
(microvascular leakage) and the wet/dry weight
(pulmonary edema) technique. The pulmonary injury
was significantly higher (5.3 ± 0.8/45.4 ± 4.3 and
6.2 ± 0.5/28.5 ± 2.1, respectively Evans blue measurement
and wet/dry weight at 2 and 24 h after intestinal I/R) in
comparison with control group (naive group: 1.2 ± 0.2/
5.6 ± 1.0; sham group: 1.0 ± 0.3/5.0 ± 1.2; negative control
group + saline: 1.2 ± 0.4/6.2 ± 1.6; negative control group
+ Ac2-26: 1.0 ± 0.5/4.9 ± 1.0) (Figure 2G-H). The
pretreatment of peptide Ac2-26 significantly reduced
pulmonary microvascular leakage 2 and 24 h after intes-
tinal I/R (3.8 ± 0.5/30.6 ± 2.5 ± 0.7/3.3 and 18.5 ± 3.0,
respectively) (Figure 2G-H).
Intestinal I/R mice also had significantly elevated lung
plasma leak into alveolar cavity, detected by protein
contents in the bronchoalveolar lavage (6.2 ± 0.6 and 8.4
± 0.6 mg/lungs, respectively 2 and 24 h after intestinal
I/R) compared to control mice (naive group: 3.9 ± 0.2;
sham group: 4.0 ± 0.4; negative control group + saline:
4.2 ± 0.3; negative control group +Ac2-26: 4.3 ± 0.5)
(Figure 2I). Peptide Ac2-26 treatment significantly attenu-
ated the plasma leak in the lung alveolar cavity at 2 and
24 h post intestinal I/R (4.2 ± 0.4 and 4.7 ± 0.6 mg/lungs,
respectively) (Figure 2I).
Effects of Ac-2-26 treatment on the IL-10 and TNF-α and
release after intestinal I/R
Figure 3 shows increased plasma level of IL-10 when mice
were subjected to 2 h of reperfusion, but after 24 h of
reperfusion, the level of this cytokine was similar to the
control group. The plasma level of TNF-α, a pro-
inflammatory cytokine, was elevated after intestinal I/R.
Peptide Ac2-26 treatment significantly augmented in-
crease (p < 0.05) in the level of IL-10 while it attenuated
increase of TNF-α (p < 0.05) at 24 h of reperfusion when
compared to levels found in non treated control mice
(Figure 3).
Effect of intestinal I/R on the annexin-A1 expression in
the lung tissue
Considering the observed pharmacological effects of
peptide Ac2-26 treatment, we decided to investigate the
expression of endogenous AnxA1 protein in the leuko-
cytes recruited into the lung due to intestinal I/R. The
primary antibody used detected both the intact and
cleaved AnxA1. However, it was not possible to distin-
guish between the two by immunohistochemistry. As
can be observed (Figure 4), control group of mice
displayed basal AnxA1 immunostaining in the cytosol
and the membrane of the leukocytes (Figure 4A). After
24 h of intestinal I/R, PBMN, alveolar monocyte/
macrophage and migrated neutrophils were highly
stained for AnxA1 (Figure 4B and Table 1), but connect-
ive tissue monocyte/macrophage and intravascular
Figure 3 Plasma IL-10 and TNF-α levels. Mice (n = 10 per group)
were submitted to intestinal ischemia-reperfusion at time 0. The
plasma concentration of IL-10 and TNF-α were determined by ELISA.
Results are mean ± SEM from two separate experiments with 5 mice
per group. **P < 0.01 and ***P < 0.001 versus control group values;
#P < 0.05 versus corresponding intestinal I/R group values.
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neutrophils showed a reduction in AnxA1 expression after
2 h of reperfusion (Table 1). After peptide Ac2-26 treat-
ment, a reduction was observed in the AnxA1 endogenous
expression in the intravascular (PBMN and PMN) and con-
nective tissue (monocyte/macrophage and neutrophils) leu-
kocytes after 24 h of intestinal I/R (Figure 4C and Table 1).
Finally, Western blotting analyzes indicated increa-
sed endogenous AnxA1 expression after intestinal I/R
(Figure 4D). However, after the peptide treatment, a
reduction in the lung tissue protein content was ob-
served, as the 37 kDa band was less intense (Figure 4D).
Interestingly, the AnxA1 cleaved at 33 kDa was highly
noticeable at 2 h post reperfusion (Figure 4D), whereas
after peptide treatment, this post-translational modifica-
tion was hardly present in all time-points (Figure 4D).
Discussion
Intestinal I/R is a risk factor for acute lung injury induc-
tion, a lung disease where activated neutrophils play a
part [2-4]. In this study, we analyzed the kinetics of
leukocyte migration to the lung after intestinal I/R and
we assessed AnxA1 expression. We also evaluated the role
of Ac2-26, the annexin-1 N-terminal peptidomimetic, on
the profile of lung tissue cells and peripheral blood
leukocytes.
Our data showed that the period of reperfusion is a
crucial factor in the changes to blood cell mobilization.
In fact, the early increase of blood neutrophils number
2 h after reperfusion was reverted 24 h later. Thus, it is
plausible to suggest that systemic inflammation caused by
intestinal I/R caused the increment of blood leukocytes,
Figure 4 Endogenous annexin-A1 expression. (A) Leukocytes from control group display basal immunostain for AnxA1 protein (arrow).
(B) After intestinal I/R, expression of the protein was augmented in the cytosol of lung connective tissue leukocytes (arrows). (C) Peptide Ac2-26
pretreatment decreases expression of AnxA1 in the leukocytes (arrows). Vessel (V). Haematoxylin-eosin counterstained. Bar, 10 μm. (D) AnxA1
protein content was also analyzed by Western blotting. A representative image of five different experiments indicates that AnxA1 expression
(37 kDa; whole protein) in the lung tissue was down regulated after peptide Ac2-26 treatment. The cleaved AnxA1 (33 kDa) was observed in the
control groups, increased after 2 h of intestinal ischemia-reperfusion and weakly present after peptide Ac2-26 treatment. Data were analyzed by
densitometry as described in material and methods.
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which migrated to target organ causing acute lung injury.
Indeed we [1,15] and others [2-4] have demonstrated an
increased influx of neutrophils into the lung and increased
microvascular permeability in rodents subjected to intes-
tinal I/R. Here, we observed that intestinal I/R intensified
influx of neutrophil into the lung tissue, as evidenced by
histological studies. Moreover, previous studies have
demonstrated an increased lung myeloperoxidase activity
due to intestinal I/R, indicating neutrophils activity at this
inflammatory site [15]. These data agree with the concept
that intestinal I/R induces remote organ injury, notably in
the lung, where endothelial barrier plays a pivotal role in
the organ injury [19]. Notwithstanding neutrophils are
the principal cells that mediate acute lung injury after
intestinal I/R. Mononuclear cells might also contribute
to lung changes caused by gut trauma [5], causing immu-
nodepression. Accordingly, innate immune response
triggered by intestinal trauma has been associated to
induction of lung failure [20]. It is noteworthy to state that
our current data revealed a time-dependent decrease of
blood monocytes and lymphocytes after intestinal I/R, a
fact that was accompanied by their concomitant increase
in the lung tissue, indicating, therefore, that these cells
were activated by intestinal trauma.
Regarding the involvement of neutrophils in the intes-
tinal I/R-induced remote organ inflammation, some
treatments for this condition have been developed. Most
of which include neutrophil depletion and direct inhib-
ition of neutrophil activators [5]. However, leukocyte or
pro-inflammatory mediator blocking may cause several
adverse side effects, because they could also affect
activation of the resolution phase of the inflammatory
response [14]. Being so, we hypothesize that AnxA1 as a
component of endogenous control of inflammatory
response could constitute a new approach to control the
magnitude of acute lung injury due to intestinal I/R. In
fact, our data demonstrated that the AnxA1 mimetic
Ac2-26 compound regulated the neutrophil trafficking
from the blood vessels into the lung after intestinal I/R,
as observed at 24 h time-point. In this scenario, Ac2-26
played a pivotal role in the control of neutrophil influx
induced by intestinal I/R as found in other models such
as heart ischemia [10,13,21,22]. To test this hypothesis,
we assessed the number of intravascular neutrophil and
those transmigrated into lung tissue after Ac2-26 treat-
ment upon intestinal I/R. Intravascular neutrophils
increased 2 h after Ac2-26 treatment followed by intes-
tinal I/R and remained unaltered 24 h later. Such
neutrophil mobilization dynamic was accompanied by a
reduced transmigration of neutrophils into lung tissue
2 h and 24 h after reperfusion. Overall, our data suggest
that the peptidomimetic Ac2-26 treatment regulates
topographic distribution of neutrophils in order to
control acute lung injury induced by intestinal I/R.
AnxA1 and its peptidomimetic Ac2-26 regulate the
leukocyte extravasation/activation through interaction
with their receptor, the formyl-peptide receptor (FPR)
[13]. Intravital-microscopy studies have demonstrated
that AnxA1 does not inhibit the leukocytes recruitment
or rolling/adhesion to the post-capillary venules, but
affects the cell migration to the inflammatory sites
[10,13]. Several studies have demonstrated that the inter-
action between AnxA1/Ac2-26 and FPR induces a regu-
lation of L-selectin and integrin CD11b expression in
neutrophils and monocytes [13,23-25].
AnxA1 action has also been studied in other experi-
mental models of I/R. In the myocardial injury induced
by I/R of the left anterior descending coronary artery,
the treatment with peptide Ac2-26 or the human recom-
binant (hr)AnxA1 inhibited leukocyte migration and
heart tissue damage [10,13,21,22]. Other models, like
renal and cerebral I/R, also demonstrated the protective
effect of AnxA1 treatment [26-28]. Moreover, some
studies have demonstrated the inhibitory action of
AnxA1 in the leukocyte migration to the intestine and
cremaster tissue induced by intestinal I/R [28,29].
For a better understanding of other AnxA1 protect-
ive effect during the intestinal I/R, we analyzed anti-
inflammatory cytokine IL-10 and the pro-inflammatory
cytokine TNF-α release. Our data indicated that the
Table 1 AnxA1 Immunohistochemistry analysis in lung leukocytes after intestinal ischemia-reperfusion
Control Intestinal I/R Intestinal I/R + Ac2-26
2 h 24 h 2 h 24 h
Intravascular PBMN 49,7 ± 7,2 55.9 ± 4.5 83,7 ± 3,1*** 65.4 ± 5.3 60,5 ± 5,2#
Alveolar monocyte/macrophage 43,2 ± 5,5 43.1 ± 4.4 66,7 ± 3,7* 44.4 ± 2.7 46,3 ± 7,3
Connective tissue monocyte/macrophage 60,2 ± 1,7 53.8 ± 2.1* 64,9 ± 1,9 45.6 ± 1.8***# 55,8 ±1,9#
Intravascular neutrophils 88,5 ± 4,2 71.3 ± 2.2*** 83,6 ± 2,7 72.6 ± 2.5*** 65,9 ± 3,0***###
Alveolar neutrophils —— 59.0 ± 3.8 80,6 ± 3,7 47.4 ± 3.4 68,1 ± 3,5
Connective tissue neutrophils 80,9 ± 2,6 71.2 ± 2.3 95,8 ± 2,9*** 69.3 ± 2.4* 70,3 ± 1,8*###
AnxA1 protein expression was analyzed in mice lung at 0, 2 and 24 h post-intestinal ischemia-reperfusion (n = 10 per group). Groups of mice were treated with
the peptide Ac2-26 (i.p.) as described in Material and Methods section. Values (densitometric units) are mean ± SEM of 10 tissue sections analyzed from five mice
per group. *P < 0.05, **P < 0.01, ***P < 0.001 versus control group values. #P < 0.05, ##P < 0.01, ###P < 0.001 versus corresponding intestinal I/R group values.
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peptide Ac2-26 treatment increased IL-10 levels and de-
crease that of TNF-α in the plasma after 24 h of intes-
tinal I/R. Several works have indicated the induction of
IL-10 release after AnxA1 treatment [29-31], and reduc-
tion of IL-10 levels in AnxA1 deficient mice [23]. On
one hand AnxA1 or peptide Ac2-26 treatment, in the
case of LPS-induced endotoxemia, inhibited TNF-α re-
lease [31,32], whereas in the absence of AnxA1, in-
creased levels of the cytokine was observed [23]. In
addition, antibodies against AnxA1 or an FPR antagon-
ist, BOC-1, caused a reduction in levels of IL-10 in the
plasma after intestinal I/R [29]. Also, it is important to
highlight that, since endogenous AnxA1 promotes con-
stitutive activation of ERK and innate immune stimula-
tors such as CpG DNA up-regulate IL-10 production in
macrophages by activating the extracellular signal-
regulated kinase (ERK) pathways, it is conceivable that
ERK signaling pathway is involved in the
effect of IL-10 up-regulation via AnxA1 administration
[33]. All these data indicate the importance of AnxA1 in
the induction of the anti-inflammatory cytokine IL-10
release and downregulation of TNF-α level, which high-
lights the importance of this protein in the regulation of
the inflammatory process. All this process might be or-
chestrated through AnxA1 receptor, FPR/ALX [29].
Finally, we also analyzed endogenous AnxA1 protein
expression by immunohistochemistry and Western
blotting techniques in the lung tissue after intestinal I/R.
Some studies have described endogenous expression of
AnxA1 in the airways, in particular alveolar macro-
phages and lung endothelial cells [23,31]. Our data
indicated reduced AnxA1 expression after peptide
Ac2-26 treatment. In contrast to our results, previous
studies have shown increase in the endogenous AnxA1
after peptide Ac2-26 treatment in leukocytes [13]. This
discrepancy can be explained by the high levels of clea-
ved AnxA1 (33 kDa) observed after intestinal I/R by
Western blotting technique. One of the possible post-
translational modifications described for these proteins
is phosphorylation, which leads to protein translocation
to the membrane and release during the inflammatory
process [34-37]. Future studies will therefore address the
secreted levels of AnxA1 after intestinal I/R.
Conclusion
In conclusion, our data indicated that AnxA1
peptidomimetic Ac2-26 treatment has both regulatory
and protective effect during lung inflammation induced
by intestinal I/R. The main mechanisms observed here
were the reduction of leukocyte migration into the lung
and the induction of the anti-inflammatory cytokine
IL-10 release in the blood. The anti-inflammatory effects
of AnxA1 as reported herein suggests that the protein
could be relevant to understanding mechanisms
underlying the pharmacological interventions to control
inflammatory events related to intestinal I/R.
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